Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.
- >190 Team members in Tuebingen and Munich, Germany and Houston, Texas
- >200 Targets covering 20 major solid and liquid tumors
- 2 proprietary technology platforms
- 9 proprietary development programs, thereof 4 in clinical trials
- Multiple partnered programs
- Raised ~$475m in cash through equity and non-dilutive funding
Privately-held Immatics was established in 2000 as a spin out from H.G. Rammensee's laboratory at the University of Tübingen, Germany. The Company was founded to develop and commercialize ground-breaking discoveries on the immunopeptidome as targets for all types of T-cell based immunotherapies.
In 2015, Immatics and MD Anderson Cancer Center (MDACC) launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.
Immatics has more than 190 team members across its three sites.
Our headquarter, discovery, research and Bispecific TCR development are in Tuebingen, while corporate, commercial and regulatory functions are in Munich. Adoptive cell therapy development and clinical manufacturing are carried out in Houston, Texas.